{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:28:59Z","timestamp":1695727739522},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1007\/s11906-004-0069-6","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T19:36:58Z","timestamp":1180035418000},"page":"195-200","source":"Crossref","is-referenced-by-count":12,"title":["Aldosterone and aldosterone antagonism in systemic hypertension"],"prefix":"10.1007","volume":"6","author":[{"given":"William H.","family":"Frishman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Charles T.","family":"Stier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","volume":"263","author":"SA Simpson","year":"1952","unstructured":"Simpson SA, Tait JF: Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 1952, 263:226\u2013228.","journal-title":"Lancet"},{"key":"69_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/bbrc.1995.2106","volume":"213","author":"M Christ","year":"1995","unstructured":"Christ M, Meyer C, Sippel K, Wehling M: Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C-alpha. Biochem Biophys Res Commun 1995, 213:123\u2013129.","journal-title":"Biochem Biophys Res Commun"},{"key":"69_CR3","first-page":"E616","volume":"272","author":"M Schneider","year":"1997","unstructured":"Schneider M, Ulsenheimer A, Christ M, Wehling M: Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol 1997, 272:E616-E620.","journal-title":"Am J Physiol"},{"key":"69_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00060793-199806000-00011","volume":"5","author":"CT Stier Jr","year":"1998","unstructured":"Stier CT Jr, Chander PN, Rocha R, et al.: Non-epithelial effects of aldosterone. Curr Opin Endocrinol Diab 1998, 5:211\u2013216.","journal-title":"Curr Opin Endocrinol Diab"},{"key":"69_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.HDX.0000061698.20666.aa","volume":"5","author":"CT Stier Jr","year":"2003","unstructured":"Stier CT Jr, Koenig S, Lee DY, et al.: Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis 2003, 5:102\u2013118. Comprehensive review of aldosterone physiology and the effects of aldosterone-receptor blockade.","journal-title":"Heart Dis"},{"key":"69_CR6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CAJ Farquharson","year":"2000","unstructured":"Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597.","journal-title":"Circulation"},{"key":"69_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11906-001-0046-2","volume":"3","author":"S Rajagopalan","year":"2001","unstructured":"Rajagopalan S, Pitt B: Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001, 3:240\u2013248.","journal-title":"Curr Hypertens Rep"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","volume":"108","author":"SL Liu","year":"2003","unstructured":"Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD: Aldosterone regulates vascular reactivity. Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400\u20132406.","journal-title":"Circulation"},{"key":"69_CR9","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893\u2013901. Report of a study describing an important nonrenal pathophysiologic action of aldosterone on blood vessels.","journal-title":"J Lab Clin Med"},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","volume":"40","author":"GP Rossi","year":"2002","unstructured":"Rossi GP, DiBello V, Ganzaroli C, et al.: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40:23\u201327. Report on a study describing a direct effect of aldosterone on the myocardium.","journal-title":"Hypertension"},{"key":"69_CR11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ajh\/4.8.680","volume":"4","author":"CT Stier Jr","year":"1991","unstructured":"Stier CT Jr, Chander PN, Gutstein WH, et al.: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991, 4:680\u2013687.","journal-title":"Am J Hypertens"},{"key":"69_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0024-3205(62)90021-8","volume":"5","author":"RB Arora","year":"1962","unstructured":"Arora RB, Somani P: Ectopic arrhythmia provoking action of aldosterone. Life Sci 1962, 5:215\u2013218.","journal-title":"Life Sci"},{"key":"69_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0002-9149(90)90476-H","volume":"66","author":"DE Vaughan","year":"1990","unstructured":"Vaughan DE, Lamas GA, Pfeffer MA: Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990, 66:529\u2013532.","journal-title":"Am J Cardiol"},{"key":"69_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1172\/JCI117809","volume":"95","author":"DE Vaughan","year":"1995","unstructured":"Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995, 95:995\u20131001.","journal-title":"J Clin Invest"},{"issue":"Suppl N","key":"69_CR15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/eurheartj\/16.suppl_N.98","volume":"16","author":"F Zannad","year":"1995","unstructured":"Zannad F: Aldosterone and heart failure. Eur Heart J 1995, 16(Suppl N):98\u2013102.","journal-title":"Eur Heart J"},{"issue":"Suppl N","key":"69_CR16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16","author":"AD Struthers","year":"1995","unstructured":"Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16 (Suppl N):103\u2013106. Report on a study showing an \"aldosterone escape\" phenomenon despite adequate ACE inhibition in humans.","journal-title":"Eur Heart J"},{"key":"69_CR17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","volume":"78","author":"RALES Investigators","year":"1996","unstructured":"RALES Investigators: Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78:902\u2013907. Report on a major trial demonstrating the efficacy of spironolactone for reducing mortality in heart failure patients with left ventricular dysfunction.","journal-title":"Am J Cardiol"},{"key":"69_CR18","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","volume":"144","author":"AD Struthers","year":"2002","unstructured":"Struthers AD: Aldosterone: cardiovascular assault. Am Heart J 2002, 144:S2\u20137.","journal-title":"Am Heart J"},{"key":"69_CR19","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1067\/mhj.2002.129971","volume":"144","author":"JW Funder","year":"2002","unstructured":"Funder JW: New biology of aldosterone and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002, 144:S8-S11. A comprehensive review of the pharmacology of a new selective aldosterone-receptor inhibitor.","journal-title":"Am Heart J"},{"key":"69_CR20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039\u20131045.","journal-title":"Hypertension"},{"key":"69_CR21","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967\u20132972. Report on a study showing the reversal of aldosterone\u2019s effects on the heart using specific receptor blockade.","journal-title":"Circulation"},{"key":"69_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/CS19980176","volume":"95","author":"KM Yee","year":"1998","unstructured":"Yee KM, Struthers AD: Aldosterone blunts the baroreflex response in man. Clin Sci 1998, 95:687\u2013692.","journal-title":"Clin Sci"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusaf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of the strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999, 100:1056\u20131064.","journal-title":"Circulation"},{"key":"69_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583\u2013585.","journal-title":"Science"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1440-1681.1987.tb02422.x","volume":"14","author":"P Pearce","year":"1987","unstructured":"Pearce P, Funder JW: High affinity aldosterone binding sites (type 1 receptors) in rat heart. Clin Exp Pharmacol Physiol 1987, 14:859\u2013866.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"69_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","volume":"92","author":"AM Lombes","year":"1995","unstructured":"Lombes AM, Alfaidy N, Eugene E, et al.: Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175\u2013182.","journal-title":"Circulation"},{"issue":"4","key":"69_CR27","first-page":"E616","volume":"272","author":"M Schneider","year":"1997","unstructured":"Schneider M, Ulsenheimer A, Christ M, Wehling M: Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol 1997, 272 (4 Part 1):E616\u2013620.","journal-title":"Am J Physiol"},{"issue":"3","key":"69_CR28","first-page":"E482","volume":"258","author":"EP Gomez-Sanchez","year":"1990","unstructured":"Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE: Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol 1990, 258 (3 Part 1):E482-E484.","journal-title":"Am J Physiol"},{"key":"69_CR29","first-page":"E657","volume":"269","author":"M Young","year":"1995","unstructured":"Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269:E657-E662. Report on an experimental study showing enhanced myocardial fibrosis from mineralocorticoid excess.","journal-title":"Am J Physiol"},{"key":"69_CR30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/01.RES.46.5.619","volume":"46","author":"KH Berecek","year":"1980","unstructured":"Berecek KH, Stocker M, Gross F: Changes in renal vascular reactivity at various stages of deoxycorticosterone hypertension in rats. Circ Res 1980, 46:619\u2013624.","journal-title":"Circ Res"},{"key":"69_CR31","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/0024-3205(82)90441-6","volume":"30","author":"MA Weber","year":"1982","unstructured":"Weber MA, Purdy RE: Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982, 30:2009\u20132017. Report on a study showing an increased vascular reactivity to catecholamines related to an effect of aldosterone.","journal-title":"Life Sci"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","volume":"19","author":"M Wang","year":"1992","unstructured":"Wang M, McClaim JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertens 1992, 19:270\u2013277.","journal-title":"Hypertens"},{"key":"69_CR33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","volume":"17","author":"A Benetos","year":"1997","unstructured":"Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997, 17:1152\u20131156.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"69_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R Rocha","year":"2001","unstructured":"Rocha R, Stier CE Jr: Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12:308\u2013314.","journal-title":"Trends Endocrinol Metab"},{"key":"69_CR35","first-page":"2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (The JNC 7 report). The National High Blood Pressure Education Program Coordinating Committee JAMA 2003, 289:2560\u20132572. Current clinical guidelines regarding the diagnosis and treatment of hypertension in the United States.","journal-title":"The National High Blood Pressure Education Program Coordinating Committee JAMA"},{"key":"69_CR36","first-page":"157","volume-title":"Cardiovascular Pharmacotherapeutics","author":"TWB Gehr","year":"2003","unstructured":"Gehr TWB, Sica DA, Frishman WH: Diuretic therapy in cardiovascular disease. In Cardiovascular Pharmacotherapeutics, edn 2. Edited by Frishman WH, Sonnenblick EH, Sica DA. New York: McGraw Hill; 2003:157\u2013176.","edition":"edn 2"},{"issue":"Suppl","key":"69_CR37","doi-asserted-by":"publisher","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02330-0","volume":"15","author":"E Burgess","year":"2002","unstructured":"Burgess E, Niegowska J, Tan W, et al.: Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension [abstract]. Am J Hypertens 2002, 15(Suppl):23A.","journal-title":"Am J Hypertens"},{"key":"69_CR38","doi-asserted-by":"publisher","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02334-8","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, MacDonald T, Conlin PR, et al.: Comparison of eplerenone and losartan in patients with low-renin hypertension. The Eplerenone 019 Investigators [abstract]. Am J Hypertens 2002, 15(4 Part 2):24A.","journal-title":"Am J Hypertens"},{"issue":"Supp_l","key":"69_CR39","doi-asserted-by":"publisher","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02331-2","volume":"15","author":"WB White","year":"2002","unstructured":"White WB, Lewin AJ, Nestel R, et al.: Comparison of selective aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminuria in systolic hypertension in older people. The Eplerenone 022 Investigators [abstract]. Am J Hypertens 2002, 15(Supp_l):23A.","journal-title":"Am J Hypertens"},{"key":"69_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716. Report on studies of eplerenone in the treatment of hypertension.","journal-title":"Am J Hypertens"},{"key":"69_CR41","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1067\/mhj.2002.129970","volume":"144","author":"MA Weber","year":"2002","unstructured":"Weber MA: Clinical implications of aldosterone blockade. Am Heart J 2002, 144:S12-S18.","journal-title":"Am Heart J"},{"key":"69_CR42","doi-asserted-by":"publisher","first-page":"46H","DOI":"10.1016\/0002-9149(88)91105-8","volume":"61","author":"MR Weir","year":"1988","unstructured":"Weir MR, Saunders E: Pharmacologic management of systemic hypertension in blacks. Am J Cardiol 1988, 61:46H-52H.","journal-title":"Am J Cardiol"},{"issue":"Suppl 5A","key":"69_CR43","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/0002-9343(91)90479-H","volume":"90","author":"MR Weir","year":"1991","unstructured":"Weir MR: Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991, 90(Suppl 5A):3S-14S.","journal-title":"Am J Med"},{"key":"69_CR44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155. Report on the use of eplerenone in hypertensive black patients. Study compares the effects of losartan and eplerenone in black and white patients.","journal-title":"J Am Coll Cardiol"},{"key":"69_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/qjmed\/92.4.187","volume":"92","author":"CR Gibbs","year":"1999","unstructured":"Gibbs CR, Beevers DG, Lip GY: The management of hypertensive disease in black patients. QJM 1999, 92:187\u2013192.","journal-title":"QJM"},{"key":"69_CR46","doi-asserted-by":"publisher","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V Jr, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination theapy in diabetic hypertensives with microalbuminuria. The Eplerenone 021 Investigators [abstract]. Am J Hypertens 2002, 15:24A.","journal-title":"Am J Hypertens"},{"key":"69_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64\u201368.","journal-title":"Hypertension"},{"key":"69_CR48","doi-asserted-by":"publisher","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02332-4","volume":"15","author":"B Pitt","year":"2002","unstructured":"Pitt B, Reichek N, Metscher B, et al.: Efficacy and safety of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in patients with left ventricular hypertrophy The Eplerenone 017 Investigators [abstract]. Am J Hypertens 2002, 15:23A.","journal-title":"Am J Hypertens"},{"key":"69_CR49","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212\u20132216. Report describing the favorable effect of aldosterone receptor antagonism on the atherosclerotic process.","journal-title":"Circulation"},{"issue":"SupplA","key":"69_CR50","doi-asserted-by":"publisher","first-page":"482a","DOI":"10.1016\/S0735-1097(04)92042-6","volume":"43","author":"D Susic","year":"2004","unstructured":"Susic D, Varagic J, Ahn I, et al.: Eplerenone improves coronary hemodynamics and reduces cardiac fibrosis in aging spontaneously hypertensive rats [abstract]. J Am Coll Cardiol 2004, 43(SupplA):482a.","journal-title":"J Am Coll Cardiol"},{"key":"69_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/01.HYP.0000105624.68174.00","volume":"43","author":"RB Paula de","year":"2004","unstructured":"de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41\u201347.","journal-title":"Hypertension"},{"key":"69_CR52","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003, 348:1309\u20131321. Report on a major study showing the benefit of the selective aldosterone receptor antagonist eplerenone in survivors of myocardial infarction who have left ventricular dysfunction.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-004-0069-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0069-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:08:37Z","timestamp":1581959317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-004-0069-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s11906-004-0069-6","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}